Lisata Therapeutics (LSTA) reported promising preclinical results for its investigational candidate, certepetide. The data showed that certepetide combined with standard-of-care chemotherapy and immunotherapy improved survival in mice with intrahepatic cholangiocarcinoma.
Kristen Buck, Chief Medical Officer at Lisata, said: "We are currently conducting a Phase 2a clinical trial, known as the BOLSTER trial, to evaluate certepetide in combination with standard-of-care chemotherapy as first-line treatment for cholangiocarcinoma. Based on the recommendations of the investigators involved in BOLSTER and the serious unmet medical need for treatments in a second line, we will soon be adding another arm to BOLSTER to test certepetide in combination with standard-of-care chemoimmunotherapy in intrahepatic cholangiocarcinoma patients."
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.